Use of fluvastatin following percutaneous coronary intervention

References

• Heart Protection Study CollaborativeGroup. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
   Google Scholar
• Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch. Intern. Med. 159(15), 1793–1802 (1999).
   PubMed Web of Science ®Google Scholar
• Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am. J. Med. 112(8A), S19–S26 (2002).
   Google Scholar
• Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33(11), 1569–1582 (1992).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100(13), 1481–1492 (1999).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program(NCEP) Expert Panel on Detection E and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• Horlitz M, Sigwart U, Niebauer J. Statins do not prevent restenosis after coronary angioplasty: where to go from here? Herz 26(2), 119–128 (2001).
   Google Scholar
• Ruygrok PN, de Jaegere PT, van Domburg RT et al. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J. Am. Coll. Cardiol. 27(7), 1669–1677 (1996).
   Google Scholar
• Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am. J. Cardiol. 82(10B), T57–T59 (1998).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Berg K, Cook TJ et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 156(18), 2085 (1996).
   PubMed Web of Science ®Google Scholar
• Flaker GC, Warnica JW, Sacks FM et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J. Am. Coll. Cardiol. 34(1), 106–112 (1999).
   PubMed Web of Science ®Google Scholar
• Hague W, Forder P, Simes J et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am. Heart J. 145(4), 643–651 (2003).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 159(22), 2661–2667 (1999).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Foley DP, Jackson G et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. 20(1), 58–69 (1999).
   PubMed Web of Science ®Google Scholar
• Horlitz M, Sigwart U, Niebauer J. Fighting restenosis after coronary angioplasty: contemporary and future treatment options. Int. J. Cardiol. 83(3), 199–205 (2002).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24), 3215–3222 (2002).
   PubMed Web of Science ®Google Scholar
• Natarajan A, Gall S, Zaman A. Statin therapy following percutaneous coronary revascularisation: time to make LIPS stick. Br. J. Cardiol. 11(2), 38–40 (2004).
   Google Scholar
• Nakamura Y, Yamaoka O, Uchida K et al. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study). Cardiovasc. Drugs Ther. 10(4), 475–483 (1996).
   Google Scholar
• O’Keefe JH Jr, Stone GW, McCallister BD Jr et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 77(8), 649–652 (1996).
   PubMedGoogle Scholar
• Mulder HJ, Bal ET, Jukema JW et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am. J. Cardiol. 86(7), 742–746 (2000).
   PubMed Web of Science ®Google Scholar
• Graham D, Staffa J, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585–2590 (2004).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ. Should rosuvastatin be withdrawn from the market? Lancet 364(9445), 1577–1578 (2004).
   Google Scholar
• Florentinus SR, Heerdink ER, Klungel OH, de Boer A. Should rosuvastatin be withdrawn from the market? Lancet 364(9445), 1577 (2004).
   Google Scholar
• Cohen JS. Should rosuvastatin be withdrawn from the market? Lancet 364(9445), 1579 (2004).
   Google Scholar
• Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S. Safety of rosuvastatin. Am. J. Cardiol. 94(7), 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet 363(9427), 2189–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Reckless JP. Fluvastatin. Expert Opin. Pharmacother. 3(11), 1631–1641 (2002).
   PubMedGoogle Scholar
• Ebrahim S, Davey Smith G, McCabe C et al. What role for statins? A review and economic model. Health Technol. Assess. 3(19), 1–91 (1999).
   Google Scholar
• Cobos A, Jovell AJ, Garcia Altes A, Garcia Closas R, Serra Majem L. Which statin is most efficient for the treatment of hypercholesterolemia? A cost–effectiveness analysis. Clin. Ther. 21(11), 1924–1936 (1999).
   PubMed Web of Science ®Google Scholar
• Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Suppl. C), C59–C65 (1998).
   PubMedGoogle Scholar
• Scuffham PA, Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. PharmacoEconomics 22(8), 525–535 (2004).
   PubMed Web of Science ®Google Scholar
• Chaplin S, Scuffham PA, Alon M, van den Boom G. Secondary prevention after PCI: the cost–effectiveness of statin therapy in the Netherlands. Netherlands Heart J. 12(7/8), 331–336 (2004).
   PubMedGoogle Scholar
• Serruys PW, Unger F, Sousa JE et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. 344(15), 1117–1124 (2001).
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. National Institute for Clinical Excellence, London, UK, (2001).
   Google Scholar
• Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br. Med. J. 323(7324), 1300–1303 (2001).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin SurvivalStudy Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383–1389 (1994).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Trial investigators. N. Engl. J. Med. 335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors – whom to treat? Eur. Heart J. 22, 751–761 (2001).
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, McNamara JR, Tayler T et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 93(1), 31–39 (2004).
   Google Scholar
• Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81(5), 582–587 (1998).
   PubMed Web of Science ®Google Scholar
• Schulte K, Bell S. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemia patients: a double-blind, parallel-group comparison. Clin. Drug Invest. 12, 119–126 (1996).
   Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. Br. Med. J. 328, 385–386 (2004).
   PubMed Web of Science ®Google Scholar
• DeWilde S, Carey IM, Bremner SA et al. Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart 89(4), 417–421 (2003).
   PubMed Web of Science ®Google Scholar
• Walter DH, Fichtlscherer S, Britten MB et al. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am. J. Cardiol. 89(1), 1–6 (2002).
   Google Scholar
• Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Suppl. C), C59–C65 (1998).
   PubMedGoogle Scholar
• Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J. Cardiovas. Pharmacol. 37(5), 502–511 (2001).
   PubMed Web of Science ®Google Scholar
• Olsson AG, Pauciullo P, Soska V et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin. Ther. 23(1), 45–61 (2001).
   PubMed Web of Science ®Google Scholar